Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer Drug Trials Could Benefit From ‘Rational’ Eligibility Criteria

Executive Summary

US FDA drug reviewers argue that enrolling more heterogeneous patient populations could result in fewer postmarketing requirements and earlier satisfaction of pediatric study obligations.

Advertisement

Related Content

Oncology Center of Excellence Open For Business: Podcast With US FDA’s Richard Pazdur
Pediatric Drug Development A Priority For US FDA’s New Oncology Center Of Excellence
Cancer Trials: Broader Eligibility Criteria Could Mean Novel Labeling Claims
FDA's Pazdur To Patient Advocates: Focus On Issues That 'Drive The Show'

Topics

Advertisement
UsernamePublicRestriction

Register

PS120452

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel